Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Phase 2 Recruiting
92 enrolled
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Phase 2 Recruiting
153 enrolled
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Phase 2 Recruiting
335 enrolled
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Phase 2 Recruiting
2,000 enrolled
Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia
Phase 2 Recruiting
20 enrolled
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Phase 2 Recruiting
147 enrolled
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Phase 2 Recruiting
153 enrolled
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Phase 2 Recruiting
93 enrolled
A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)
Phase 2 Recruiting
22 enrolled
Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Phase 2 Recruiting
14 enrolled
TAILOR
Phase 2 Recruiting
320 enrolled
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
Phase 2 Recruiting
33 enrolled
STOP VEN
Phase 2 Recruiting
50 enrolled
Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
Phase 2 Recruiting
33 enrolled
TRILLIUM
Phase 2 Recruiting
83 enrolled
A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia
Phase 2 Recruiting
45 enrolled
Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.
Phase 2 Recruiting
56 enrolled
GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
Phase 2 Recruiting
40 enrolled
Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD
Phase 2 Recruiting
37 enrolled
Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2 Recruiting
168 enrolled
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
Phase 2 Recruiting
60 enrolled
A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)
Phase 2 Recruiting
30 enrolled
SELVEDge
Phase 2 Recruiting
33 enrolled
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
Phase 2 Recruiting
52 enrolled
Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia
Phase 2 Recruiting
52 enrolled
Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
Phase 2 Recruiting
30 enrolled
ReVenG
Phase 2 Recruiting
75 enrolled
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
Phase 2 Recruiting
40 enrolled
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
Phase 2 Recruiting
52 enrolled
TAGALONG
Phase 2 Recruiting
53 enrolled
Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
Phase 2 Recruiting
102 enrolled
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Phase 2 Recruiting
160 enrolled
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
Phase 2 Recruiting
91 enrolled 26 charts
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 2 Recruiting
110 enrolled
A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
Phase 2 Recruiting
66 enrolled
Cladribine Venetoclax in Monocytic AML
Phase 2 Recruiting
20 enrolled
Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms
Phase 2 Recruiting
40 enrolled
Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
Phase 2 Recruiting
53 enrolled
Venetoclax Combined With Azactidine in the Treatment of ALAL
Phase 2 Recruiting
23 enrolled
Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
Phase 2 Recruiting
68 enrolled
VIWA-1
Phase 2 Recruiting
80 enrolled
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
Phase 2 Recruiting
90 enrolled
Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia
Phase 2 Recruiting
92 enrolled
Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial
Phase 2 Recruiting
20 enrolled
Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML
Phase 2 Recruiting
240 enrolled
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Phase 2 Recruiting
40 enrolled
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
Phase 2 Recruiting
172 enrolled
Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
Phase 2 Recruiting
40 enrolled
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
Phase 2 Recruiting
30 enrolled
Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2 Recruiting
27 enrolled